#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Naltrexone ameliorates functional network abnormalities in alcohol‐dependent individuals Abstract Naltrexone, an opioid receptor antagonist, is commonly used as a relapse prevention medication in alcohol and opiate addiction, but its efficacy and the mechanisms underpinning its clinical usefulness are not well characterized.
1-1	0-10	Naltrexone	_
1-2	11-22	ameliorates	_
1-3	23-33	functional	_
1-4	34-41	network	_
1-5	42-55	abnormalities	_
1-6	56-58	in	_
1-7	59-76	alcohol‐dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-8	77-88	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-9	89-97	Abstract	_
1-10	98-108	Naltrexone	_
1-11	109-110	,	_
1-12	111-113	an	_
1-13	114-120	opioid	_
1-14	121-129	receptor	_
1-15	130-140	antagonist	_
1-16	141-142	,	_
1-17	143-145	is	_
1-18	146-154	commonly	_
1-19	155-159	used	_
1-20	160-162	as	_
1-21	163-164	a	_
1-22	165-172	relapse	_
1-23	173-183	prevention	_
1-24	184-194	medication	_
1-25	195-197	in	_
1-26	198-205	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-27	206-209	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-28	210-216	opiate	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
1-29	217-226	addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
1-30	227-228	,	_
1-31	229-232	but	_
1-32	233-236	its	_
1-33	237-245	efficacy	_
1-34	246-249	and	_
1-35	250-253	the	_
1-36	254-264	mechanisms	_
1-37	265-277	underpinning	_
1-38	278-281	its	_
1-39	282-290	clinical	_
1-40	291-301	usefulness	_
1-41	302-305	are	_
1-42	306-309	not	_
1-43	310-314	well	_
1-44	315-328	characterized	_
1-45	329-330	.	_

Text=In the current study, we examined the effects of 50‐mg naltrexone compared with placebo on neural network changes associated with substance dependence in 21 alcohol and 36 poly‐drug‐dependent individuals compared with 36 healthy volunteers.
2-1	331-333	In	_
2-2	334-337	the	_
2-3	338-345	current	_
2-4	346-351	study	_
2-5	352-353	,	_
2-6	354-356	we	_
2-7	357-365	examined	_
2-8	366-369	the	_
2-9	370-377	effects	_
2-10	378-380	of	_
2-11	381-386	50‐mg	_
2-12	387-397	naltrexone	_
2-13	398-406	compared	_
2-14	407-411	with	_
2-15	412-419	placebo	_
2-16	420-422	on	_
2-17	423-429	neural	_
2-18	430-437	network	_
2-19	438-445	changes	_
2-20	446-456	associated	_
2-21	457-461	with	_
2-22	462-471	substance	_
2-23	472-482	dependence	_
2-24	483-485	in	_
2-25	486-488	21	_
2-26	489-496	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
2-27	497-500	and	_
2-28	501-503	36	_
2-29	504-523	poly‐drug‐dependent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
2-30	524-535	individuals	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
2-31	536-544	compared	_
2-32	545-549	with	_
2-33	550-552	36	_
2-34	553-560	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-35	561-571	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-36	572-573	.	_

Text=Graph theoretic and network‐based statistical analysis of resting‐state functional magnetic resonance imaging (MRI) data revealed that alcohol‐dependent subjects had reduced functional connectivity of a dispersed network compared with both poly‐drug‐dependent and healthy subjects.
3-1	574-579	Graph	_
3-2	580-589	theoretic	_
3-3	590-593	and	_
3-4	594-607	network‐based	_
3-5	608-619	statistical	_
3-6	620-628	analysis	_
3-7	629-631	of	_
3-8	632-645	resting‐state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-9	646-656	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-10	657-665	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-11	666-675	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-12	676-683	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-13	684-685	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-14	686-689	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-15	690-691	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-16	692-696	data	_
3-17	697-705	revealed	_
3-18	706-710	that	_
3-19	711-728	alcohol‐dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
3-20	729-737	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
3-21	738-741	had	_
3-22	742-749	reduced	_
3-23	750-760	functional	_
3-24	761-773	connectivity	_
3-25	774-776	of	_
3-26	777-778	a	_
3-27	779-788	dispersed	_
3-28	789-796	network	_
3-29	797-805	compared	_
3-30	806-810	with	_
3-31	811-815	both	_
3-32	816-835	poly‐drug‐dependent	_
3-33	836-839	and	_
3-34	840-847	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-35	848-856	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-36	857-858	.	_

Text=Higher local efficiency was observed in both patient groups, indicating clustered and segregated network topology and information processing.
4-1	859-865	Higher	_
4-2	866-871	local	_
4-3	872-882	efficiency	_
4-4	883-886	was	_
4-5	887-895	observed	_
4-6	896-898	in	_
4-7	899-903	both	_
4-8	904-911	patient	_
4-9	912-918	groups	_
4-10	919-920	,	_
4-11	921-931	indicating	_
4-12	932-941	clustered	_
4-13	942-945	and	_
4-14	946-956	segregated	_
4-15	957-964	network	_
4-16	965-973	topology	_
4-17	974-977	and	_
4-18	978-989	information	_
4-19	990-1000	processing	_
4-20	1001-1002	.	_

Text=Naltrexone normalized heightened local efficiency of the neural network in alcohol‐dependent individuals, to the same levels as healthy volunteers.
5-1	1003-1013	Naltrexone	_
5-2	1014-1024	normalized	_
5-3	1025-1035	heightened	_
5-4	1036-1041	local	_
5-5	1042-1052	efficiency	_
5-6	1053-1055	of	_
5-7	1056-1059	the	_
5-8	1060-1066	neural	_
5-9	1067-1074	network	_
5-10	1075-1077	in	_
5-11	1078-1095	alcohol‐dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
5-12	1096-1107	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
5-13	1108-1109	,	_
5-14	1110-1112	to	_
5-15	1113-1116	the	_
5-16	1117-1121	same	_
5-17	1122-1128	levels	_
5-18	1129-1131	as	_
5-19	1132-1139	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-20	1140-1150	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-21	1151-1152	.	_

Text=Naltrexone failed to have an effect on the local efficiency in abstinent poly‐substance‐dependent individuals.
6-1	1153-1163	Naltrexone	_
6-2	1164-1170	failed	_
6-3	1171-1173	to	_
6-4	1174-1178	have	_
6-5	1179-1181	an	_
6-6	1182-1188	effect	_
6-7	1189-1191	on	_
6-8	1192-1195	the	_
6-9	1196-1201	local	_
6-10	1202-1212	efficiency	_
6-11	1213-1215	in	_
6-12	1216-1225	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
6-13	1226-1250	poly‐substance‐dependent	_
6-14	1251-1262	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-15	1263-1264	.	_

Text=Across groups, local efficiency was associated with substance, but no alcohol exposure implicating local efficiency as a potential premorbid risk factor in alcohol use disorders that can be ameliorated by naltrexone.
7-1	1265-1271	Across	_
7-2	1272-1278	groups	_
7-3	1279-1280	,	_
7-4	1281-1286	local	_
7-5	1287-1297	efficiency	_
7-6	1298-1301	was	_
7-7	1302-1312	associated	_
7-8	1313-1317	with	_
7-9	1318-1327	substance	_
7-10	1328-1329	,	_
7-11	1330-1333	but	_
7-12	1334-1336	no	_
7-13	1337-1344	alcohol	_
7-14	1345-1353	exposure	_
7-15	1354-1365	implicating	_
7-16	1366-1371	local	_
7-17	1372-1382	efficiency	_
7-18	1383-1385	as	_
7-19	1386-1387	a	_
7-20	1388-1397	potential	_
7-21	1398-1407	premorbid	_
7-22	1408-1412	risk	_
7-23	1413-1419	factor	_
7-24	1420-1422	in	_
7-25	1423-1430	alcohol	_
7-26	1431-1434	use	_
7-27	1435-1444	disorders	_
7-28	1445-1449	that	_
7-29	1450-1453	can	_
7-30	1454-1456	be	_
7-31	1457-1468	ameliorated	_
7-32	1469-1471	by	_
7-33	1472-1482	naltrexone	_
7-34	1483-1484	.	_

Text=These findings suggest one possible mechanism for the clinical effects of naltrexone, namely, the amelioration of disrupted network topology.
8-1	1485-1490	These	_
8-2	1491-1499	findings	_
8-3	1500-1507	suggest	_
8-4	1508-1511	one	_
8-5	1512-1520	possible	_
8-6	1521-1530	mechanism	_
8-7	1531-1534	for	_
8-8	1535-1538	the	_
8-9	1539-1547	clinical	_
8-10	1548-1555	effects	_
8-11	1556-1558	of	_
8-12	1559-1569	naltrexone	_
8-13	1570-1571	,	_
8-14	1572-1578	namely	_
8-15	1579-1580	,	_
8-16	1581-1584	the	_
8-17	1585-1597	amelioration	_
8-18	1598-1600	of	_
8-19	1601-1610	disrupted	_
8-20	1611-1618	network	_
8-21	1619-1627	topology	_
8-22	1628-1629	.	_

Text=Materials and Methods Participants Details of study design and procedures are reported elsewhere (Paterson et al.
9-1	1630-1639	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-2	1640-1643	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-3	1644-1651	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-4	1652-1664	Participants	_
9-5	1665-1672	Details	_
9-6	1673-1675	of	_
9-7	1676-1681	study	_
9-8	1682-1688	design	_
9-9	1689-1692	and	_
9-10	1693-1703	procedures	_
9-11	1704-1707	are	_
9-12	1708-1716	reported	_
9-13	1717-1726	elsewhere	_
9-14	1727-1728	(	_
9-15	1729-1737	Paterson	_
9-16	1738-1740	et	_
9-17	1741-1743	al	_
9-18	1744-1745	.	_

Text=2015).
10-1	1746-1750	2015	_
10-2	1751-1752	)	_
10-3	1753-1754	.	_

Text=Inclusion criteria included individuals who met DSM‐IV criteria for current or prior AD, or another substance of dependence (e.g.
11-1	1755-1764	Inclusion	_
11-2	1765-1773	criteria	_
11-3	1774-1782	included	_
11-4	1783-1794	individuals	_
11-5	1795-1798	who	_
11-6	1799-1802	met	_
11-7	1803-1809	DSM‐IV	_
11-8	1810-1818	criteria	_
11-9	1819-1822	for	_
11-10	1823-1830	current	_
11-11	1831-1833	or	_
11-12	1834-1839	prior	_
11-13	1840-1842	AD	_
11-14	1843-1844	,	_
11-15	1845-1847	or	_
11-16	1848-1855	another	_
11-17	1856-1865	substance	_
11-18	1866-1868	of	_
11-19	1869-1879	dependence	_
11-20	1880-1881	(	_
11-21	1882-1885	e.g	_
11-22	1886-1887	.	_

Text=amphetamines, benzodiazepines, cocaine and opiates) (poly‐drug SD).
12-1	1888-1900	amphetamines	_
12-2	1901-1902	,	_
12-3	1903-1918	benzodiazepines	_
12-4	1919-1920	,	_
12-5	1921-1928	cocaine	_
12-6	1929-1932	and	_
12-7	1933-1940	opiates	_
12-8	1941-1942	)	_
12-9	1943-1944	(	_
12-10	1945-1954	poly‐drug	_
12-11	1955-1957	SD	_
12-12	1958-1959	)	_
12-13	1960-1961	.	_

Text=Participants were abstinent, and there was no upper limit for abstinence.
13-1	1962-1974	Participants	_
13-2	1975-1979	were	_
13-3	1980-1989	abstinent	_
13-4	1990-1991	,	_
13-5	1992-1995	and	_
13-6	1996-2001	there	_
13-7	2002-2005	was	_
13-8	2006-2008	no	_
13-9	2009-2014	upper	_
13-10	2015-2020	limit	_
13-11	2021-2024	for	_
13-12	2025-2035	abstinence	_
13-13	2036-2037	.	_

Text=Abstinence was determined through clinical interviews during the baseline session and by using urine and alcohol breath test on each day of testing.
14-1	2038-2048	Abstinence	_
14-2	2049-2052	was	_
14-3	2053-2063	determined	_
14-4	2064-2071	through	_
14-5	2072-2080	clinical	_
14-6	2081-2091	interviews	_
14-7	2092-2098	during	_
14-8	2099-2102	the	_
14-9	2103-2111	baseline	_
14-10	2112-2119	session	_
14-11	2120-2123	and	_
14-12	2124-2126	by	_
14-13	2127-2132	using	_
14-14	2133-2138	urine	_
14-15	2139-2142	and	_
14-16	2143-2150	alcohol	_
14-17	2151-2157	breath	_
14-18	2158-2162	test	_
14-19	2163-2165	on	_
14-20	2166-2170	each	_
14-21	2171-2174	day	_
14-22	2175-2177	of	_
14-23	2178-2185	testing	_
14-24	2186-2187	.	_

Text=Participants were not undergoing pharmacological treatment.
15-1	2188-2200	Participants	_
15-2	2201-2205	were	_
15-3	2206-2209	not	_
15-4	2210-2220	undergoing	_
15-5	2221-2236	pharmacological	_
15-6	2237-2246	treatment	_
15-7	2247-2248	.	_

Text=All participants were aged 21 to 64 years.
16-1	2249-2252	All	_
16-2	2253-2265	participants	_
16-3	2266-2270	were	_
16-4	2271-2275	aged	_
16-5	2276-2278	21	_
16-6	2279-2281	to	_
16-7	2282-2284	64	_
16-8	2285-2290	years	_
16-9	2291-2292	.	_

Text=The healthy control group had no previous history of substance abuse, as assessed using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) (Group WAW 2002) and timeline follow‐back.
17-1	2293-2296	The	_
17-2	2297-2304	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-3	2305-2312	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-4	2313-2318	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-5	2319-2322	had	_
17-6	2323-2325	no	_
17-7	2326-2334	previous	_
17-8	2335-2342	history	_
17-9	2343-2345	of	_
17-10	2346-2355	substance	_
17-11	2356-2361	abuse	_
17-12	2362-2363	,	_
17-13	2364-2366	as	_
17-14	2367-2375	assessed	_
17-15	2376-2381	using	_
17-16	2382-2385	the	_
17-17	2386-2393	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-18	2394-2395	,	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-19	2396-2403	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-20	2404-2407	and	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-21	2408-2417	Substance	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-22	2418-2429	Involvement	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-23	2430-2439	Screening	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-24	2440-2444	Test	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-25	2445-2446	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-26	2447-2453	ASSIST	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-27	2454-2455	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
17-28	2456-2457	(	_
17-29	2458-2463	Group	_
17-30	2464-2467	WAW	_
17-31	2468-2472	2002	_
17-32	2473-2474	)	_
17-33	2475-2478	and	_
17-34	2479-2487	timeline	_
17-35	2488-2499	follow‐back	_
17-36	2500-2501	.	_

Text=The healthy control group was matched for age, gender and smoking status where possible.
18-1	2502-2505	The	_
18-2	2506-2513	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-3	2514-2521	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-4	2522-2527	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-5	2528-2531	was	_
18-6	2532-2539	matched	_
18-7	2540-2543	for	_
18-8	2544-2547	age	_
18-9	2548-2549	,	_
18-10	2550-2556	gender	_
18-11	2557-2560	and	_
18-12	2561-2568	smoking	_
18-13	2569-2575	status	_
18-14	2576-2581	where	_
18-15	2582-2590	possible	_
18-16	2591-2592	.	_

Text=All participants were required to provide a negative breath alcohol test and a negative urine sample (screening for the presence of amphetamines, benzodiazepines, cocaine and opiates) on experimental days.
19-1	2593-2596	All	_
19-2	2597-2609	participants	_
19-3	2610-2614	were	_
19-4	2615-2623	required	_
19-5	2624-2626	to	_
19-6	2627-2634	provide	_
19-7	2635-2636	a	_
19-8	2637-2645	negative	_
19-9	2646-2652	breath	_
19-10	2653-2660	alcohol	_
19-11	2661-2665	test	_
19-12	2666-2669	and	_
19-13	2670-2671	a	_
19-14	2672-2680	negative	_
19-15	2681-2686	urine	_
19-16	2687-2693	sample	_
19-17	2694-2695	(	_
19-18	2696-2705	screening	_
19-19	2706-2709	for	_
19-20	2710-2713	the	_
19-21	2714-2722	presence	_
19-22	2723-2725	of	_
19-23	2726-2738	amphetamines	_
19-24	2739-2740	,	_
19-25	2741-2756	benzodiazepines	_
19-26	2757-2758	,	_
19-27	2759-2766	cocaine	_
19-28	2767-2770	and	_
19-29	2771-2778	opiates	_
19-30	2779-2780	)	_
19-31	2781-2783	on	_
19-32	2784-2796	experimental	_
19-33	2797-2801	days	_
19-34	2802-2803	.	_

Text=Participants were asked to refrain from cannabis use for the 7 days prior to testing.
20-1	2804-2816	Participants	_
20-2	2817-2821	were	_
20-3	2822-2827	asked	_
20-4	2828-2830	to	_
20-5	2831-2838	refrain	_
20-6	2839-2843	from	_
20-7	2844-2852	cannabis	_
20-8	2853-2856	use	_
20-9	2857-2860	for	_
20-10	2861-2864	the	_
20-11	2865-2866	7	_
20-12	2867-2871	days	_
20-13	2872-2877	prior	_
20-14	2878-2880	to	_
20-15	2881-2888	testing	_
20-16	2889-2890	.	_

Text=Positive results for cannabinoids were accepted; however, because of the long half‐life of metabolites, so long as the participant was not under intoxication or withdrawal.
21-1	2891-2899	Positive	_
21-2	2900-2907	results	_
21-3	2908-2911	for	_
21-4	2912-2924	cannabinoids	_
21-5	2925-2929	were	_
21-6	2930-2938	accepted	_
21-7	2939-2940	;	_
21-8	2941-2948	however	_
21-9	2949-2950	,	_
21-10	2951-2958	because	_
21-11	2959-2961	of	_
21-12	2962-2965	the	_
21-13	2966-2970	long	_
21-14	2971-2980	half‐life	_
21-15	2981-2983	of	_
21-16	2984-2995	metabolites	_
21-17	2996-2997	,	_
21-18	2998-3000	so	_
21-19	3001-3005	long	_
21-20	3006-3008	as	_
21-21	3009-3012	the	_
21-22	3013-3024	participant	_
21-23	3025-3028	was	_
21-24	3029-3032	not	_
21-25	3033-3038	under	_
21-26	3039-3051	intoxication	_
21-27	3052-3054	or	_
21-28	3055-3065	withdrawal	_
21-29	3066-3067	.	_

Text=For the alcohol group, prior dependence on any other substance was exclusionary.
22-1	3068-3071	For	_
22-2	3072-3075	the	_
22-3	3076-3083	alcohol	_
22-4	3084-3089	group	_
22-5	3090-3091	,	_
22-6	3092-3097	prior	_
22-7	3098-3108	dependence	_
22-8	3109-3111	on	_
22-9	3112-3115	any	_
22-10	3116-3121	other	_
22-11	3122-3131	substance	_
22-12	3132-3135	was	_
22-13	3136-3148	exclusionary	_
22-14	3149-3150	.	_

Text=Exclusion criteria included are as follows: current use of regular prescription or non‐prescription medication that would interfere with study integrity or subject safety; current primary axis I diagnosis; current or past history of enduring severe mental illness; current or past psychiatric history that contraindicated participation; history or current significant neurological diagnosis that may have influenced analysis or results; claustrophobia or unable to lie in the MRI scanner for 90 minutes; a cardiac pacemaker, other electronic device or other MRI contraindication, including pregnancy, as assessed by a standard pre‐MRI questionnaire.
23-1	3151-3160	Exclusion	_
23-2	3161-3169	criteria	_
23-3	3170-3178	included	_
23-4	3179-3182	are	_
23-5	3183-3185	as	_
23-6	3186-3193	follows	_
23-7	3194-3195	:	_
23-8	3196-3203	current	_
23-9	3204-3207	use	_
23-10	3208-3210	of	_
23-11	3211-3218	regular	_
23-12	3219-3231	prescription	_
23-13	3232-3234	or	_
23-14	3235-3251	non‐prescription	_
23-15	3252-3262	medication	_
23-16	3263-3267	that	_
23-17	3268-3273	would	_
23-18	3274-3283	interfere	_
23-19	3284-3288	with	_
23-20	3289-3294	study	_
23-21	3295-3304	integrity	_
23-22	3305-3307	or	_
23-23	3308-3315	subject	_
23-24	3316-3322	safety	_
23-25	3323-3324	;	_
23-26	3325-3332	current	_
23-27	3333-3340	primary	_
23-28	3341-3345	axis	_
23-29	3346-3347	I	_
23-30	3348-3357	diagnosis	_
23-31	3358-3359	;	_
23-32	3360-3367	current	_
23-33	3368-3370	or	_
23-34	3371-3375	past	_
23-35	3376-3383	history	_
23-36	3384-3386	of	_
23-37	3387-3395	enduring	_
23-38	3396-3402	severe	_
23-39	3403-3409	mental	_
23-40	3410-3417	illness	_
23-41	3418-3419	;	_
23-42	3420-3427	current	_
23-43	3428-3430	or	_
23-44	3431-3435	past	_
23-45	3436-3447	psychiatric	_
23-46	3448-3455	history	_
23-47	3456-3460	that	_
23-48	3461-3476	contraindicated	_
23-49	3477-3490	participation	_
23-50	3491-3492	;	_
23-51	3493-3500	history	_
23-52	3501-3503	or	_
23-53	3504-3511	current	_
23-54	3512-3523	significant	_
23-55	3524-3536	neurological	_
23-56	3537-3546	diagnosis	_
23-57	3547-3551	that	_
23-58	3552-3555	may	_
23-59	3556-3560	have	_
23-60	3561-3571	influenced	_
23-61	3572-3580	analysis	_
23-62	3581-3583	or	_
23-63	3584-3591	results	_
23-64	3592-3593	;	_
23-65	3594-3608	claustrophobia	_
23-66	3609-3611	or	_
23-67	3612-3618	unable	_
23-68	3619-3621	to	_
23-69	3622-3625	lie	_
23-70	3626-3628	in	_
23-71	3629-3632	the	_
23-72	3633-3636	MRI	_
23-73	3637-3644	scanner	_
23-74	3645-3648	for	_
23-75	3649-3651	90	_
23-76	3652-3659	minutes	_
23-77	3660-3661	;	_
23-78	3662-3663	a	_
23-79	3664-3671	cardiac	_
23-80	3672-3681	pacemaker	_
23-81	3682-3683	,	_
23-82	3684-3689	other	_
23-83	3690-3700	electronic	_
23-84	3701-3707	device	_
23-85	3708-3710	or	_
23-86	3711-3716	other	_
23-87	3717-3720	MRI	_
23-88	3721-3737	contraindication	_
23-89	3738-3739	,	_
23-90	3740-3749	including	_
23-91	3750-3759	pregnancy	_
23-92	3760-3761	,	_
23-93	3762-3764	as	_
23-94	3765-3773	assessed	_
23-95	3774-3776	by	_
23-96	3777-3778	a	_
23-97	3779-3787	standard	_
23-98	3788-3795	pre‐MRI	_
23-99	3796-3809	questionnaire	_
23-100	3810-3811	.	_

Text=Secondary or lifetime history of depression or anxiety was permitted in both SD and healthy volunteers, as these are common comorbidities in the former.
24-1	3812-3821	Secondary	_
24-2	3822-3824	or	_
24-3	3825-3833	lifetime	_
24-4	3834-3841	history	_
24-5	3842-3844	of	_
24-6	3845-3855	depression	_
24-7	3856-3858	or	_
24-8	3859-3866	anxiety	_
24-9	3867-3870	was	_
24-10	3871-3880	permitted	_
24-11	3881-3883	in	_
24-12	3884-3888	both	_
24-13	3889-3891	SD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
24-14	3892-3895	and	_
24-15	3896-3903	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
24-16	3904-3914	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
24-17	3915-3916	,	_
24-18	3917-3919	as	_
24-19	3920-3925	these	_
24-20	3926-3929	are	_
24-21	3930-3936	common	_
24-22	3937-3950	comorbidities	_
24-23	3951-3953	in	_
24-24	3954-3957	the	_
24-25	3958-3964	former	_
24-26	3965-3966	.	_

Text=Procedure All participants underwent a baseline session followed by two study sessions in which clinical, cognitive and neuroimaging tests were completed under either placebo or naltrexone, in counterbalanced order.
25-1	3967-3976	Procedure	_
25-2	3977-3980	All	_
25-3	3981-3993	participants	_
25-4	3994-4003	underwent	_
25-5	4004-4005	a	_
25-6	4006-4014	baseline	_
25-7	4015-4022	session	_
25-8	4023-4031	followed	_
25-9	4032-4034	by	_
25-10	4035-4038	two	_
25-11	4039-4044	study	_
25-12	4045-4053	sessions	_
25-13	4054-4056	in	_
25-14	4057-4062	which	_
25-15	4063-4071	clinical	_
25-16	4072-4073	,	_
25-17	4074-4083	cognitive	_
25-18	4084-4087	and	_
25-19	4088-4100	neuroimaging	_
25-20	4101-4106	tests	_
25-21	4107-4111	were	_
25-22	4112-4121	completed	_
25-23	4122-4127	under	_
25-24	4128-4134	either	_
25-25	4135-4142	placebo	_
25-26	4143-4145	or	_
25-27	4146-4156	naltrexone	_
25-28	4157-4158	,	_
25-29	4159-4161	in	_
25-30	4162-4177	counterbalanced	_
25-31	4178-4183	order	_
25-32	4184-4185	.	_

Text=The drug was administered 2 hours before each scan.
26-1	4186-4189	The	_
26-2	4190-4194	drug	_
26-3	4195-4198	was	_
26-4	4199-4211	administered	_
26-5	4212-4213	2	_
26-6	4214-4219	hours	_
26-7	4220-4226	before	_
26-8	4227-4231	each	_
26-9	4232-4236	scan	_
26-10	4237-4238	.	_

Text=A 50‐mg oral dose of naltrexone (manufactured by Bristol‐Myers Squibb Pharmaceutical Limited, UK) provided as per the British National Formulary was administered per participant.
27-1	4239-4240	A	_
27-2	4241-4246	50‐mg	_
27-3	4247-4251	oral	_
27-4	4252-4256	dose	_
27-5	4257-4259	of	_
27-6	4260-4270	naltrexone	_
27-7	4271-4272	(	_
27-8	4273-4285	manufactured	_
27-9	4286-4288	by	_
27-10	4289-4302	Bristol‐Myers	_
27-11	4303-4309	Squibb	_
27-12	4310-4324	Pharmaceutical	_
27-13	4325-4332	Limited	_
27-14	4333-4334	,	_
27-15	4335-4337	UK	_
27-16	4338-4339	)	_
27-17	4340-4348	provided	_
27-18	4349-4351	as	_
27-19	4352-4355	per	_
27-20	4356-4359	the	_
27-21	4360-4367	British	_
27-22	4368-4376	National	_
27-23	4377-4386	Formulary	_
27-24	4387-4390	was	_
27-25	4391-4403	administered	_
27-26	4404-4407	per	_
27-27	4408-4419	participant	_
27-28	4420-4421	.	_

Text=Subjects participated in resting state functional MRI, which was always first, and followed by three task‐based functional MRI scans.
28-1	4422-4430	Subjects	_
28-2	4431-4443	participated	_
28-3	4444-4446	in	_
28-4	4447-4454	resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-5	4455-4460	state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-6	4461-4471	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-7	4472-4475	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-8	4476-4477	,	_
28-9	4478-4483	which	_
28-10	4484-4487	was	_
28-11	4488-4494	always	_
28-12	4495-4500	first	_
28-13	4501-4502	,	_
28-14	4503-4506	and	_
28-15	4507-4515	followed	_
28-16	4516-4518	by	_
28-17	4519-4524	three	_
28-18	4525-4535	task‐based	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-19	4536-4546	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-20	4547-4550	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-21	4551-4556	scans	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-22	4557-4558	.	_

Text=We examined individuals who completed both study sessions, which were counterbalanced, and there were no participant dropouts between these sessions (36 healthy volunteers [17 placebo first, Imperial/Cambridge/Manchester (ICM) = 13/12/11]; 36 poly‐drug SD (19 placebo first, ICM = 12/13/11); 21 AD (12 placebo first, ICM = 10/6/5)).
29-1	4559-4561	We	_
29-2	4562-4570	examined	_
29-3	4571-4582	individuals	_
29-4	4583-4586	who	_
29-5	4587-4596	completed	_
29-6	4597-4601	both	_
29-7	4602-4607	study	_
29-8	4608-4616	sessions	_
29-9	4617-4618	,	_
29-10	4619-4624	which	_
29-11	4625-4629	were	_
29-12	4630-4645	counterbalanced	_
29-13	4646-4647	,	_
29-14	4648-4651	and	_
29-15	4652-4657	there	_
29-16	4658-4662	were	_
29-17	4663-4665	no	_
29-18	4666-4677	participant	_
29-19	4678-4686	dropouts	_
29-20	4687-4694	between	_
29-21	4695-4700	these	_
29-22	4701-4709	sessions	_
29-23	4710-4711	(	_
29-24	4712-4714	36	_
29-25	4715-4722	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
29-26	4723-4733	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
29-27	4734-4735	[	_
29-28	4736-4738	17	_
29-29	4739-4746	placebo	_
29-30	4747-4752	first	_
29-31	4753-4754	,	_
29-32	4755-4784	Imperial/Cambridge/Manchester	_
29-33	4785-4786	(	_
29-34	4787-4790	ICM	_
29-35	4791-4792	)	_
29-36	4793-4794	=	_
29-37	4795-4803	13/12/11	_
29-38	4804-4805	]	_
29-39	4806-4807	;	_
29-40	4808-4810	36	_
29-41	4811-4820	poly‐drug	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
29-42	4821-4823	SD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
29-43	4824-4825	(	_
29-44	4826-4828	19	_
29-45	4829-4836	placebo	_
29-46	4837-4842	first	_
29-47	4843-4844	,	_
29-48	4845-4848	ICM	_
29-49	4849-4850	=	_
29-50	4851-4859	12/13/11	_
29-51	4860-4861	)	_
29-52	4862-4863	;	_
29-53	4864-4866	21	_
29-54	4867-4869	AD	_
29-55	4870-4871	(	_
29-56	4872-4874	12	_
29-57	4875-4882	placebo	_
29-58	4883-4888	first	_
29-59	4889-4890	,	_
29-60	4891-4894	ICM	_
29-61	4895-4896	=	_
29-62	4897-4903	10/6/5	_
29-63	4904-4905	)	_
29-64	4906-4907	)	_
29-65	4908-4909	.	_

Text=Please see Supporting Information for further details of procedure and assessments taken.
30-1	4910-4916	Please	_
30-2	4917-4920	see	_
30-3	4921-4931	Supporting	_
30-4	4932-4943	Information	_
30-5	4944-4947	for	_
30-6	4948-4955	further	_
30-7	4956-4963	details	_
30-8	4964-4966	of	_
30-9	4967-4976	procedure	_
30-10	4977-4980	and	_
30-11	4981-4992	assessments	_
30-12	4993-4998	taken	_
30-13	4999-5000	.	_

Text=Resting State Functional MRI Acquisition and Processing Data acquisition procedures are reported elsewhere (McGonigle et al.
31-1	5001-5008	Resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-2	5009-5014	State	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-3	5015-5025	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-4	5026-5029	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-5	5030-5041	Acquisition	_
31-6	5042-5045	and	_
31-7	5046-5056	Processing	_
31-8	5057-5061	Data	_
31-9	5062-5073	acquisition	_
31-10	5074-5084	procedures	_
31-11	5085-5088	are	_
31-12	5089-5097	reported	_
31-13	5098-5107	elsewhere	_
31-14	5108-5109	(	_
31-15	5110-5119	McGonigle	_
31-16	5120-5122	et	_
31-17	5123-5125	al	_
31-18	5126-5127	.	_

Text=2016).
32-1	5128-5132	2016	_
32-2	5133-5134	)	_
32-3	5135-5136	.	_

Text=Briefly, data were collected from three centres in the United Kingdom (Imperial College London and University of Cambridge with 3T Siemens Tim Trio with a Siemens 32 channel head coil, and Salford Royal NHS Foundation Trust, Manchester using 3T Philips Achieva with an eight‐element SENSE head coil).
33-1	5137-5144	Briefly	_
33-2	5145-5146	,	_
33-3	5147-5151	data	_
33-4	5152-5156	were	_
33-5	5157-5166	collected	_
33-6	5167-5171	from	_
33-7	5172-5177	three	_
33-8	5178-5185	centres	_
33-9	5186-5188	in	_
33-10	5189-5192	the	_
33-11	5193-5199	United	_
33-12	5200-5207	Kingdom	_
33-13	5208-5209	(	_
33-14	5210-5218	Imperial	_
33-15	5219-5226	College	_
33-16	5227-5233	London	_
33-17	5234-5237	and	_
33-18	5238-5248	University	_
33-19	5249-5251	of	_
33-20	5252-5261	Cambridge	_
33-21	5262-5266	with	_
33-22	5267-5269	3T	_
33-23	5270-5277	Siemens	_
33-24	5278-5281	Tim	_
33-25	5282-5286	Trio	_
33-26	5287-5291	with	_
33-27	5292-5293	a	_
33-28	5294-5301	Siemens	_
33-29	5302-5304	32	_
33-30	5305-5312	channel	_
33-31	5313-5317	head	_
33-32	5318-5322	coil	_
33-33	5323-5324	,	_
33-34	5325-5328	and	_
33-35	5329-5336	Salford	_
33-36	5337-5342	Royal	_
33-37	5343-5346	NHS	_
33-38	5347-5357	Foundation	_
33-39	5358-5363	Trust	_
33-40	5364-5365	,	_
33-41	5366-5376	Manchester	_
33-42	5377-5382	using	_
33-43	5383-5385	3T	_
33-44	5386-5393	Philips	_
33-45	5394-5401	Achieva	_
33-46	5402-5406	with	_
33-47	5407-5409	an	_
33-48	5410-5423	eight‐element	_
33-49	5424-5429	SENSE	_
33-50	5430-5434	head	_
33-51	5435-5439	coil	_
33-52	5440-5441	)	_
33-53	5442-5443	.	_

Text=A recent report (McGonigle et al.
34-1	5444-5445	A	_
34-2	5446-5452	recent	_
34-3	5453-5459	report	_
34-4	5460-5461	(	_
34-5	5462-5471	McGonigle	_
34-6	5472-5474	et	_
34-7	5475-5477	al	_
34-8	5478-5479	.	_

Text=2016) demonstrated no differences between centres for neuroimaging results during task performance, using the exact same data acquisition sequences and processing in healthy volunteers.
35-1	5480-5484	2016	_
35-2	5485-5486	)	_
35-3	5487-5499	demonstrated	_
35-4	5500-5502	no	_
35-5	5503-5514	differences	_
35-6	5515-5522	between	_
35-7	5523-5530	centres	_
35-8	5531-5534	for	_
35-9	5535-5547	neuroimaging	_
35-10	5548-5555	results	_
35-11	5556-5562	during	_
35-12	5563-5567	task	_
35-13	5568-5579	performance	_
35-14	5580-5581	,	_
35-15	5582-5587	using	_
35-16	5588-5591	the	_
35-17	5592-5597	exact	_
35-18	5598-5602	same	_
35-19	5603-5607	data	_
35-20	5608-5619	acquisition	_
35-21	5620-5629	sequences	_
35-22	5630-5633	and	_
35-23	5634-5644	processing	_
35-24	5645-5647	in	_
35-25	5648-5655	healthy	_
35-26	5656-5666	volunteers	_
35-27	5667-5668	.	_

Text=Please see Supporting Information for further details.
36-1	5669-5675	Please	_
36-2	5676-5679	see	_
36-3	5680-5690	Supporting	_
36-4	5691-5702	Information	_
36-5	5703-5706	for	_
36-6	5707-5714	further	_
36-7	5715-5722	details	_
36-8	5723-5724	.	_

Text=Resting state functional MRI data were collected for 360 seconds from all participants with eyes closed.
37-1	5725-5732	Resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-2	5733-5738	state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-3	5739-5749	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-4	5750-5753	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-5	5754-5758	data	_
37-6	5759-5763	were	_
37-7	5764-5773	collected	_
37-8	5774-5777	for	_
37-9	5778-5781	360	_
37-10	5782-5789	seconds	_
37-11	5790-5794	from	_
37-12	5795-5798	all	_
37-13	5799-5811	participants	_
37-14	5812-5816	with	_
37-15	5817-5821	eyes	_
37-16	5822-5828	closed	_
37-17	5829-5830	.	_

Text=Participants were asked to think of nothing in particular.
38-1	5831-5843	Participants	_
38-2	5844-5848	were	_
38-3	5849-5854	asked	_
38-4	5855-5857	to	_
38-5	5858-5863	think	_
38-6	5864-5866	of	_
38-7	5867-5874	nothing	_
38-8	5875-5877	in	_
38-9	5878-5888	particular	_
38-10	5889-5890	.	_

Text=Data were pre‐processed using speedypp.py as part of the fMRI signal processing toolbox v1.0, which draws upon modules from afni toolbox (http: //afni.nimh.nih.gov).
39-1	5891-5895	Data	_
39-2	5896-5900	were	_
39-3	5901-5914	pre‐processed	_
39-4	5915-5920	using	_
39-5	5921-5932	speedypp.py	_
39-6	5933-5935	as	_
39-7	5936-5940	part	_
39-8	5941-5943	of	_
39-9	5944-5947	the	_
39-10	5948-5952	fMRI	_
39-11	5953-5959	signal	_
39-12	5960-5970	processing	_
39-13	5971-5978	toolbox	_
39-14	5979-5983	v1.0	_
39-15	5984-5985	,	_
39-16	5986-5991	which	_
39-17	5992-5997	draws	_
39-18	5998-6002	upon	_
39-19	6003-6010	modules	_
39-20	6011-6015	from	_
39-21	6016-6020	afni	_
39-22	6021-6028	toolbox	_
39-23	6029-6030	(	_
39-24	6031-6035	http	_
39-25	6036-6037	:	_
39-26	6038-6057	//afni.nimh.nih.gov	_
39-27	6058-6059	)	_
39-28	6060-6061	.	_

Text=As motion significantly affects connectivity measures during resting state fMRI, motion parameters and derivatives and signal from cerebrospinal fluid were regressed out.
40-1	6062-6064	As	_
40-2	6065-6071	motion	_
40-3	6072-6085	significantly	_
40-4	6086-6093	affects	_
40-5	6094-6106	connectivity	_
40-6	6107-6115	measures	_
40-7	6116-6122	during	_
40-8	6123-6130	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-9	6131-6136	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-10	6137-6141	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-11	6142-6143	,	_
40-12	6144-6150	motion	_
40-13	6151-6161	parameters	_
40-14	6162-6165	and	_
40-15	6166-6177	derivatives	_
40-16	6178-6181	and	_
40-17	6182-6188	signal	_
40-18	6189-6193	from	_
40-19	6194-6207	cerebrospinal	_
40-20	6208-6213	fluid	_
40-21	6214-6218	were	_
40-22	6219-6228	regressed	_
40-23	6229-6232	out	_
40-24	6233-6234	.	_

Text=Signals with high change in BOLD signal from volume to volume, i.e.
41-1	6235-6242	Signals	_
41-2	6243-6247	with	_
41-3	6248-6252	high	_
41-4	6253-6259	change	_
41-5	6260-6262	in	_
41-6	6263-6267	BOLD	_
41-7	6268-6274	signal	_
41-8	6275-6279	from	_
41-9	6280-6286	volume	_
41-10	6287-6289	to	_
41-11	6290-6296	volume	_
41-12	6297-6298	,	_
41-13	6299-6302	i.e	_
41-14	6303-6304	.	_

Text=dvars> 2, may not have been sufficiently corrected for motion (Power et al.
42-1	6305-6310	dvars	_
42-2	6311-6312	>	_
42-3	6313-6314	2	_
42-4	6315-6316	,	_
42-5	6317-6320	may	_
42-6	6321-6324	not	_
42-7	6325-6329	have	_
42-8	6330-6334	been	_
42-9	6335-6347	sufficiently	_
42-10	6348-6357	corrected	_
42-11	6358-6361	for	_
42-12	6362-6368	motion	_
42-13	6369-6370	(	_
42-14	6371-6376	Power	_
42-15	6377-6379	et	_
42-16	6380-6382	al	_
42-17	6383-6384	.	_

Text=2012), and these subjects were removed in a secondary, more stringent analysis, resulting in removal of three AD, 10 poly‐drug SD and eight HV participants.
43-1	6385-6389	2012	_
43-2	6390-6391	)	_
43-3	6392-6393	,	_
43-4	6394-6397	and	_
43-5	6398-6403	these	_
43-6	6404-6412	subjects	_
43-7	6413-6417	were	_
43-8	6418-6425	removed	_
43-9	6426-6428	in	_
43-10	6429-6430	a	_
43-11	6431-6440	secondary	_
43-12	6441-6442	,	_
43-13	6443-6447	more	_
43-14	6448-6457	stringent	_
43-15	6458-6466	analysis	_
43-16	6467-6468	,	_
43-17	6469-6478	resulting	_
43-18	6479-6481	in	_
43-19	6482-6489	removal	_
43-20	6490-6492	of	_
43-21	6493-6498	three	_
43-22	6499-6501	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
43-23	6502-6503	,	_
43-24	6504-6506	10	_
43-25	6507-6516	poly‐drug	_
43-26	6517-6519	SD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
43-27	6520-6523	and	_
43-28	6524-6529	eight	_
43-29	6530-6532	HV	http://maven.renci.org/NeuroBridge/neurobridge#Thing
43-30	6533-6545	participants	_
43-31	6546-6547	.	_

Text=Dvars were not significantly different between groups (P> 0.05).
44-1	6548-6553	Dvars	_
44-2	6554-6558	were	_
44-3	6559-6562	not	_
44-4	6563-6576	significantly	_
44-5	6577-6586	different	_
44-6	6587-6594	between	_
44-7	6595-6601	groups	_
44-8	6602-6603	(	_
44-9	6604-6605	P	_
44-10	6606-6607	>	_
44-11	6608-6612	0.05	_
44-12	6613-6614	)	_
44-13	6615-6616	.	_

Text=Data were zero‐padded, despiked and slice‐time corrected.
45-1	6617-6621	Data	_
45-2	6622-6626	were	_
45-3	6627-6638	zero‐padded	_
45-4	6639-6640	,	_
45-5	6641-6649	despiked	_
45-6	6650-6653	and	_
45-7	6654-6664	slice‐time	_
45-8	6665-6674	corrected	_
45-9	6675-6676	.	_

Text=Anatomical and functional images were co‐registered and normalized to a Montreal Neurological Institute (MNI152) template.
46-1	6677-6687	Anatomical	_
46-2	6688-6691	and	_
46-3	6692-6702	functional	_
46-4	6703-6709	images	_
46-5	6710-6714	were	_
46-6	6715-6728	co‐registered	_
46-7	6729-6732	and	_
46-8	6733-6743	normalized	_
46-9	6744-6746	to	_
46-10	6747-6748	a	_
46-11	6749-6757	Montreal	_
46-12	6758-6770	Neurological	_
46-13	6771-6780	Institute	_
46-14	6781-6782	(	_
46-15	6783-6789	MNI152	_
46-16	6790-6791	)	_
46-17	6792-6800	template	_
46-18	6801-6802	.	_

Text=Graph Theory Analysis We extracted regional mean fMRI time series for 90 regions of interest (ROI) in the Anatomical Automatic Labeling template (Tzourio‐Mazoyer et al.
47-1	6803-6808	Graph	_
47-2	6809-6815	Theory	_
47-3	6816-6824	Analysis	_
47-4	6825-6827	We	_
47-5	6828-6837	extracted	_
47-6	6838-6846	regional	_
47-7	6847-6851	mean	_
47-8	6852-6856	fMRI	_
47-9	6857-6861	time	_
47-10	6862-6868	series	_
47-11	6869-6872	for	_
47-12	6873-6875	90	_
47-13	6876-6883	regions	_
47-14	6884-6886	of	_
47-15	6887-6895	interest	_
47-16	6896-6897	(	_
47-17	6898-6901	ROI	_
47-18	6902-6903	)	_
47-19	6904-6906	in	_
47-20	6907-6910	the	_
47-21	6911-6921	Anatomical	_
47-22	6922-6931	Automatic	_
47-23	6932-6940	Labeling	_
47-24	6941-6949	template	_
47-25	6950-6951	(	_
47-26	6952-6967	Tzourio‐Mazoyer	_
47-27	6968-6970	et	_
47-28	6971-6973	al	_
47-29	6974-6975	.	_

Text=2002) for each individual.
48-1	6976-6980	2002	_
48-2	6981-6982	)	_
48-3	6983-6986	for	_
48-4	6987-6991	each	_
48-5	6992-7002	individual	_
48-6	7003-7004	.	_

Text=Each regional mean time series was decomposed into wavelet coefficients at four scales using the maximum overlap discrete wavelet transform, a time‐frequency transformation.
49-1	7005-7009	Each	_
49-2	7010-7018	regional	_
49-3	7019-7023	mean	_
49-4	7024-7028	time	_
49-5	7029-7035	series	_
49-6	7036-7039	was	_
49-7	7040-7050	decomposed	_
49-8	7051-7055	into	_
49-9	7056-7063	wavelet	_
49-10	7064-7076	coefficients	_
49-11	7077-7079	at	_
49-12	7080-7084	four	_
49-13	7085-7091	scales	_
49-14	7092-7097	using	_
49-15	7098-7101	the	_
49-16	7102-7109	maximum	_
49-17	7110-7117	overlap	_
49-18	7118-7126	discrete	_
49-19	7127-7134	wavelet	_
49-20	7135-7144	transform	_
49-21	7145-7146	,	_
49-22	7147-7148	a	_
49-23	7149-7163	time‐frequency	_
49-24	7164-7178	transformation	_
49-25	7179-7180	.	_

Text=We used the scale 2 wavelet correlation matrices, which represent functionally relevant signals in the frequency range of 0.061~0.125 Hz, in line with previous reports assessing network efficiency measures (Achard & Bullmore 2007).
50-1	7181-7183	We	_
50-2	7184-7188	used	_
50-3	7189-7192	the	_
50-4	7193-7198	scale	_
50-5	7199-7200	2	_
50-6	7201-7208	wavelet	_
50-7	7209-7220	correlation	_
50-8	7221-7229	matrices	_
50-9	7230-7231	,	_
50-10	7232-7237	which	_
50-11	7238-7247	represent	_
50-12	7248-7260	functionally	_
50-13	7261-7269	relevant	_
50-14	7270-7277	signals	_
50-15	7278-7280	in	_
50-16	7281-7284	the	_
50-17	7285-7294	frequency	_
50-18	7295-7300	range	_
50-19	7301-7303	of	_
50-20	7304-7315	0.061~0.125	_
50-21	7316-7318	Hz	_
50-22	7319-7320	,	_
50-23	7321-7323	in	_
50-24	7324-7328	line	_
50-25	7329-7333	with	_
50-26	7334-7342	previous	_
50-27	7343-7350	reports	_
50-28	7351-7360	assessing	_
50-29	7361-7368	network	_
50-30	7369-7379	efficiency	_
50-31	7380-7388	measures	_
50-32	7389-7390	(	_
50-33	7391-7397	Achard	_
50-34	7398-7399	&	_
50-35	7400-7408	Bullmore	_
50-36	7409-7413	2007	_
50-37	7414-7415	)	_
50-38	7416-7417	.	_

Text=We constructed a whole brain ROI‐to‐ROI correlation matrix using pairwise region‐to‐region correlations between coefficients, as described in a previous study (Achard & Bullmore 2007).
51-1	7418-7420	We	_
51-2	7421-7432	constructed	_
51-3	7433-7434	a	_
51-4	7435-7440	whole	_
51-5	7441-7446	brain	_
51-6	7447-7457	ROI‐to‐ROI	_
51-7	7458-7469	correlation	_
51-8	7470-7476	matrix	_
51-9	7477-7482	using	_
51-10	7483-7491	pairwise	_
51-11	7492-7508	region‐to‐region	_
51-12	7509-7521	correlations	_
51-13	7522-7529	between	_
51-14	7530-7542	coefficients	_
51-15	7543-7544	,	_
51-16	7545-7547	as	_
51-17	7548-7557	described	_
51-18	7558-7560	in	_
51-19	7561-7562	a	_
51-20	7563-7571	previous	_
51-21	7572-7577	study	_
51-22	7578-7579	(	_
51-23	7580-7586	Achard	_
51-24	7587-7588	&	_
51-25	7589-7597	Bullmore	_
51-26	7598-7602	2007	_
51-27	7603-7604	)	_
51-28	7605-7606	.	_

Text=The functional connectivity weights were binarized with the density threshold of 5 percent to control network density between subjects (Achard & Bullmore 2007) and reduce the possibility of spurious connections, thus being the most parsimonious threshold generating the core connectivity of the network.
52-1	7607-7610	The	_
52-2	7611-7621	functional	_
52-3	7622-7634	connectivity	_
52-4	7635-7642	weights	_
52-5	7643-7647	were	_
52-6	7648-7657	binarized	_
52-7	7658-7662	with	_
52-8	7663-7666	the	_
52-9	7667-7674	density	_
52-10	7675-7684	threshold	_
52-11	7685-7687	of	_
52-12	7688-7689	5	_
52-13	7690-7697	percent	_
52-14	7698-7700	to	_
52-15	7701-7708	control	_
52-16	7709-7716	network	_
52-17	7717-7724	density	_
52-18	7725-7732	between	_
52-19	7733-7741	subjects	_
52-20	7742-7743	(	_
52-21	7744-7750	Achard	_
52-22	7751-7752	&	_
52-23	7753-7761	Bullmore	_
52-24	7762-7766	2007	_
52-25	7767-7768	)	_
52-26	7769-7772	and	_
52-27	7773-7779	reduce	_
52-28	7780-7783	the	_
52-29	7784-7795	possibility	_
52-30	7796-7798	of	_
52-31	7799-7807	spurious	_
52-32	7808-7819	connections	_
52-33	7820-7821	,	_
52-34	7822-7826	thus	_
52-35	7827-7832	being	_
52-36	7833-7836	the	_
52-37	7837-7841	most	_
52-38	7842-7854	parsimonious	_
52-39	7855-7864	threshold	_
52-40	7865-7875	generating	_
52-41	7876-7879	the	_
52-42	7880-7884	core	_
52-43	7885-7897	connectivity	_
52-44	7898-7900	of	_
52-45	7901-7904	the	_
52-46	7905-7912	network	_
52-47	7913-7914	.	_

Text=Whole Brain Network Characteristics Local and global efficiency in the binarized graph were computed as described in previous literature (Meunier et al.
53-1	7915-7920	Whole	_
53-2	7921-7926	Brain	_
53-3	7927-7934	Network	_
53-4	7935-7950	Characteristics	_
53-5	7951-7956	Local	_
53-6	7957-7960	and	_
53-7	7961-7967	global	_
53-8	7968-7978	efficiency	_
53-9	7979-7981	in	_
53-10	7982-7985	the	_
53-11	7986-7995	binarized	_
53-12	7996-8001	graph	_
53-13	8002-8006	were	_
53-14	8007-8015	computed	_
53-15	8016-8018	as	_
53-16	8019-8028	described	_
53-17	8029-8031	in	_
53-18	8032-8040	previous	_
53-19	8041-8051	literature	_
53-20	8052-8053	(	_
53-21	8054-8061	Meunier	_
53-22	8062-8064	et	_
53-23	8065-8067	al	_
53-24	8068-8069	.	_

Text=2009; Rubinov & Sporns 2010).
54-1	8070-8074	2009	_
54-2	8075-8076	;	_
54-3	8077-8084	Rubinov	_
54-4	8085-8086	&	_
54-5	8087-8093	Sporns	_
54-6	8094-8098	2010	_
54-7	8099-8100	)	_
54-8	8101-8102	.	_

Text=Local and global efficiency measures were entered into repeated measures ANOVA assessing group as a between‐subject factor and drug as a within‐subject factor.
55-1	8103-8108	Local	_
55-2	8109-8112	and	_
55-3	8113-8119	global	_
55-4	8120-8130	efficiency	_
55-5	8131-8139	measures	_
55-6	8140-8144	were	_
55-7	8145-8152	entered	_
55-8	8153-8157	into	_
55-9	8158-8166	repeated	_
55-10	8167-8175	measures	_
55-11	8176-8181	ANOVA	_
55-12	8182-8191	assessing	_
55-13	8192-8197	group	_
55-14	8198-8200	as	_
55-15	8201-8202	a	_
55-16	8203-8218	between‐subject	_
55-17	8219-8225	factor	_
55-18	8226-8229	and	_
55-19	8230-8234	drug	_
55-20	8235-8237	as	_
55-21	8238-8239	a	_
55-22	8240-8254	within‐subject	_
55-23	8255-8261	factor	_
55-24	8262-8263	.	_

Text=Comparisons were made using placebo, as a drug‐control session; however, the baseline session was additionally assessed to examine variability across sessions for each subject group.
56-1	8264-8275	Comparisons	_
56-2	8276-8280	were	_
56-3	8281-8285	made	_
56-4	8286-8291	using	_
56-5	8292-8299	placebo	_
56-6	8300-8301	,	_
56-7	8302-8304	as	_
56-8	8305-8306	a	_
56-9	8307-8319	drug‐control	_
56-10	8320-8327	session	_
56-11	8328-8329	;	_
56-12	8330-8337	however	_
56-13	8338-8339	,	_
56-14	8340-8343	the	_
56-15	8344-8352	baseline	_
56-16	8353-8360	session	_
56-17	8361-8364	was	_
56-18	8365-8377	additionally	_
56-19	8378-8386	assessed	_
56-20	8387-8389	to	_
56-21	8390-8397	examine	_
56-22	8398-8409	variability	_
56-23	8410-8416	across	_
56-24	8417-8425	sessions	_
56-25	8426-8429	for	_
56-26	8430-8434	each	_
56-27	8435-8442	subject	_
56-28	8443-8448	group	_
56-29	8449-8450	.	_

Text=The AD and poly‐drug SD groups were then separately compared with the HV group.
57-1	8451-8454	The	_
57-2	8455-8457	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
57-3	8458-8461	and	_
57-4	8462-8471	poly‐drug	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
57-5	8472-8474	SD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
57-6	8475-8481	groups	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
57-7	8482-8486	were	_
57-8	8487-8491	then	_
57-9	8492-8502	separately	_
57-10	8503-8511	compared	_
57-11	8512-8516	with	_
57-12	8517-8520	the	_
57-13	8521-8523	HV	http://maven.renci.org/NeuroBridge/neurobridge#Thing
57-14	8524-8529	group	_
57-15	8530-8531	.	_

Text=Local and global efficiency were correlated with drug and alcohol exposure using Pearson's correlation.
58-1	8532-8537	Local	_
58-2	8538-8541	and	_
58-3	8542-8548	global	_
58-4	8549-8559	efficiency	_
58-5	8560-8564	were	_
58-6	8565-8575	correlated	_
58-7	8576-8580	with	_
58-8	8581-8585	drug	_
58-9	8586-8589	and	_
58-10	8590-8597	alcohol	_
58-11	8598-8606	exposure	_
58-12	8607-8612	using	_
58-13	8613-8620	Pearson	_
58-14	8621-8623	's	_
58-15	8624-8635	correlation	_
58-16	8636-8637	.	_

Text=Outcomes of P <0.05 were considered significant.
59-1	8638-8646	Outcomes	_
59-2	8647-8649	of	_
59-3	8650-8651	P	_
59-4	8652-8653	<	_
59-5	8654-8658	0.05	_
59-6	8659-8663	were	_
59-7	8664-8674	considered	_
59-8	8675-8686	significant	_
59-9	8687-8688	.	_

Text=Nodal efficiency was examined on an exploratory basis for significant main findings.
60-1	8689-8694	Nodal	_
60-2	8695-8705	efficiency	_
60-3	8706-8709	was	_
60-4	8710-8718	examined	_
60-5	8719-8721	on	_
60-6	8722-8724	an	_
60-7	8725-8736	exploratory	_
60-8	8737-8742	basis	_
60-9	8743-8746	for	_
60-10	8747-8758	significant	_
60-11	8759-8763	main	_
60-12	8764-8772	findings	_
60-13	8773-8774	.	_

Text=Network‐based Statistics Group comparisons in region‐to‐region connectivity were assessed using NBS Toolbox (Zalesky et al.
61-1	8775-8788	Network‐based	_
61-2	8789-8799	Statistics	_
61-3	8800-8805	Group	_
61-4	8806-8817	comparisons	_
61-5	8818-8820	in	_
61-6	8821-8837	region‐to‐region	_
61-7	8838-8850	connectivity	_
61-8	8851-8855	were	_
61-9	8856-8864	assessed	_
61-10	8865-8870	using	_
61-11	8871-8874	NBS	_
61-12	8875-8882	Toolbox	_
61-13	8883-8884	(	_
61-14	8885-8892	Zalesky	_
61-15	8893-8895	et	_
61-16	8896-8898	al	_
61-17	8899-8900	.	_

Text=2010), for MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States).
62-1	8901-8905	2010	_
62-2	8906-8907	)	_
62-3	8908-8909	,	_
62-4	8910-8913	for	_
62-5	8914-8920	MATLAB	_
62-6	8921-8922	(	_
62-7	8923-8926	The	_
62-8	8927-8936	MathWorks	_
62-9	8937-8938	,	_
62-10	8939-8943	Inc.	_
62-11	8944-8945	,	_
62-12	8946-8952	Natick	_
62-13	8953-8954	,	_
62-14	8955-8968	Massachusetts	_
62-15	8969-8970	,	_
62-16	8971-8977	United	_
62-17	8978-8984	States	_
62-18	8985-8986	)	_
62-19	8987-8988	.	_

Text=Group differences are tested at every connection within the connectivity matrices (inter‐regional correlation in BOLD activity) using an initial threshold of T> 3 as described in the work of Zalesky et al (2010).
63-1	8989-8994	Group	_
63-2	8995-9006	differences	_
63-3	9007-9010	are	_
63-4	9011-9017	tested	_
63-5	9018-9020	at	_
63-6	9021-9026	every	_
63-7	9027-9037	connection	_
63-8	9038-9044	within	_
63-9	9045-9048	the	_
63-10	9049-9061	connectivity	_
63-11	9062-9070	matrices	_
63-12	9071-9072	(	_
63-13	9073-9087	inter‐regional	_
63-14	9088-9099	correlation	_
63-15	9100-9102	in	_
63-16	9103-9107	BOLD	_
63-17	9108-9116	activity	_
63-18	9117-9118	)	_
63-19	9119-9124	using	_
63-20	9125-9127	an	_
63-21	9128-9135	initial	_
63-22	9136-9145	threshold	_
63-23	9146-9148	of	_
63-24	9149-9150	T	_
63-25	9151-9152	>	_
63-26	9153-9154	3	_
63-27	9155-9157	as	_
63-28	9158-9167	described	_
63-29	9168-9170	in	_
63-30	9171-9174	the	_
63-31	9175-9179	work	_
63-32	9180-9182	of	_
63-33	9183-9190	Zalesky	_
63-34	9191-9193	et	_
63-35	9194-9196	al	_
63-36	9197-9198	(	_
63-37	9199-9203	2010	_
63-38	9204-9205	)	_
63-39	9206-9207	.	_

Text=NBS identified the interconnected subnetwork consisting of suprathreshold edges (T> 3 in group difference).
64-1	9208-9211	NBS	_
64-2	9212-9222	identified	_
64-3	9223-9226	the	_
64-4	9227-9241	interconnected	_
64-5	9242-9252	subnetwork	_
64-6	9253-9263	consisting	_
64-7	9264-9266	of	_
64-8	9267-9281	suprathreshold	_
64-9	9282-9287	edges	_
64-10	9288-9289	(	_
64-11	9290-9291	T	_
64-12	9292-9293	>	_
64-13	9294-9295	3	_
64-14	9296-9298	in	_
64-15	9299-9304	group	_
64-16	9305-9315	difference	_
64-17	9316-9317	)	_
64-18	9318-9319	.	_

Text=The size of the interconnected subnetwork (i.e.
65-1	9320-9323	The	_
65-2	9324-9328	size	_
65-3	9329-9331	of	_
65-4	9332-9335	the	_
65-5	9336-9350	interconnected	_
65-6	9351-9361	subnetwork	_
65-7	9362-9363	(	_
65-8	9364-9367	i.e	_
65-9	9368-9369	.	_

Text=the number of interconnected suprathreshold edges) was used to calculate a family‐wise error corrected P‐value using 10 000 permutation tests (P <0.05, family‐wise error corrected).
66-1	9370-9373	the	_
66-2	9374-9380	number	_
66-3	9381-9383	of	_
66-4	9384-9398	interconnected	_
66-5	9399-9413	suprathreshold	_
66-6	9414-9419	edges	_
66-7	9420-9421	)	_
66-8	9422-9425	was	_
66-9	9426-9430	used	_
66-10	9431-9433	to	_
66-11	9434-9443	calculate	_
66-12	9444-9445	a	_
66-13	9446-9457	family‐wise	_
66-14	9458-9463	error	_
66-15	9464-9473	corrected	_
66-16	9474-9481	P‐value	_
66-17	9482-9487	using	_
66-18	9488-9490	10	_
66-19	9491-9494	000	_
66-20	9495-9506	permutation	_
66-21	9507-9512	tests	_
66-22	9513-9514	(	_
66-23	9515-9516	P	_
66-24	9517-9518	<	_
66-25	9519-9523	0.05	_
66-26	9524-9525	,	_
66-27	9526-9537	family‐wise	_
66-28	9538-9543	error	_
66-29	9544-9553	corrected	_
66-30	9554-9555	)	_
66-31	9556-9557	.	_

Text=In other words, NBS identified an interconnected subnetwork of altered connectivity with a cluster‐level corrected P‐values using network cluster size (the number of interconnected suprathreshold edges).
67-1	9558-9560	In	_
67-2	9561-9566	other	_
67-3	9567-9572	words	_
67-4	9573-9574	,	_
67-5	9575-9578	NBS	_
67-6	9579-9589	identified	_
67-7	9590-9592	an	_
67-8	9593-9607	interconnected	_
67-9	9608-9618	subnetwork	_
67-10	9619-9621	of	_
67-11	9622-9629	altered	_
67-12	9630-9642	connectivity	_
67-13	9643-9647	with	_
67-14	9648-9649	a	_
67-15	9650-9663	cluster‐level	_
67-16	9664-9673	corrected	_
67-17	9674-9682	P‐values	_
67-18	9683-9688	using	_
67-19	9689-9696	network	_
67-20	9697-9704	cluster	_
67-21	9705-9709	size	_
67-22	9710-9711	(	_
67-23	9712-9715	the	_
67-24	9716-9722	number	_
67-25	9723-9725	of	_
67-26	9726-9740	interconnected	_
67-27	9741-9755	suprathreshold	_
67-28	9756-9761	edges	_
67-29	9762-9763	)	_
67-30	9764-9765	.	_

Text=AD and poly‐drug SD were separately compared with HV.
68-1	9766-9768	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
68-2	9769-9772	and	_
68-3	9773-9782	poly‐drug	_
68-4	9783-9785	SD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
68-5	9786-9790	were	_
68-6	9791-9801	separately	_
68-7	9802-9810	compared	_
68-8	9811-9815	with	_
68-9	9816-9818	HV	http://maven.renci.org/NeuroBridge/neurobridge#Thing
68-10	9819-9820	.	_

Text=AD and poly‐drug SD were compared with each other on an exploratory basis.
69-1	9821-9823	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
69-2	9824-9827	and	_
69-3	9828-9837	poly‐drug	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
69-4	9838-9840	SD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
69-5	9841-9845	were	_
69-6	9846-9854	compared	_
69-7	9855-9859	with	_
69-8	9860-9864	each	_
69-9	9865-9870	other	_
69-10	9871-9873	on	_
69-11	9874-9876	an	_
69-12	9877-9888	exploratory	_
69-13	9889-9894	basis	_
69-14	9895-9896	.	_

